Comparative Pharmacology
Head-to-head clinical analysis: FASENRA versus SYNAGIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FASENRA versus SYNAGIS.
FASENRA vs SYNAGIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benralizumab is a humanized afucosylated monoclonal antibody that binds to the alpha subunit of the interleukin-5 receptor (IL-5Rα) expressed on eosinophils and basophils. This binding inhibits IL-5-mediated signaling and induces antibody-dependent cell-mediated cytotoxicity (ADCC), resulting in rapid and near-complete depletion of eosinophils from blood and tissues.
Palivizumab is a humanized monoclonal antibody that binds to the A antigenic site of the fusion (F) protein of respiratory syncytial virus (RSV), inhibiting viral entry into host cells by preventing fusion of the viral envelope with the host cell membrane.
30 mg subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks thereafter.
15 mg/kg intramuscular once monthly during RSV season. Maximum dose: 300 mg (2 mL) per injection.
None Documented
None Documented
Terminal half-life approximately 25 days (range 24–27 days), supporting every-4-week subcutaneous dosing.
18-27 days (terminal half-life in pediatric patients, mean ~21 days). Allows monthly dosing during RSV season.
Degraded into small peptides and amino acids via general protein catabolism; no significant renal or biliary/fecal excretion of intact drug.
Renal: minimal intact IgG recovered in urine; likely catabolized to peptides/amino acids. Fecal/biliary: not significantly eliminated. Main route: proteolytic catabolism.
Category C
Category C
Monoclonal Antibody, Anti-Interleukin-5 Receptor
Monoclonal Antibody